基于证据的乌纳尼药理学治疗非酒精性脂肪性肝病：机制综述。

Evidence-Based Unani Pharmacotherapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease: A Mechanistic Review.

出版信息

Altern Ther Health Med. 2024 Aug;30(8):32-42.

Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) has emerged as a global health crisis, affecting a quarter of the world's population, and is anticipated to become a leading cause of liver transplantation and hepatocellular carcinoma by 2030. Conventional pharmacotherapy for NAFLD remains imperfect. In this context, Unani medicine offers a promising alternative for managing NAFLD.

OBJECTIVE

This review aims to compile information on Unani medications used for the treatment of NAFLD, aiming to provide evidence of their efficacy and delve into the mechanisms through which these Unani drugs exert their therapeutic effects in NAFLD.

METHODS

A comprehensive exploration of classical Unani literature was conducted, referencing well-established texts to extract pertinent information regarding NAFLD and its treatment in Unani Medicine. Electronic databases, including PubMed, Science Direct, and Google Scholar, were systematically searched to gather information on the efficacy of Unani drugs in the treatment of NAFLD.

RESULTS

Unani medicine offers a rich repository of single herbs and compound formulations. There is a description of about 32 single herbs and 18 compound formulations for the treatment of NAFLD. These drugs act due to their Musakhkhin (calorific), Mudirr (diuretics), Mufattiḥ (deobstruent), Muqawwῑ-i-Jigar (hepatoprotective), and Muḥallilat (anti-inflammatory) action. The bioactive components present in these drugs possess antioxidant, hypolipidemic, anti-inflammatory, hypoglycemic, and hepatoprotective activities. These actions of Unani drugs closely align with the multifaceted nature of NAFLD pathogenesis, and thus effective in the treatment of NAFLD.

CONCLUSION

The findings led us to conclude that the use of Unani medicines can improve clinical outcomes in NAFLD, as demonstrated by various clinical and experimental trials. However, further clinical trials are essential to provide a safe and effective option for addressing this prevalent liver condition.

摘要

背景

非酒精性脂肪性肝病（NAFLD）已成为全球性健康危机，影响全球四分之一的人口，预计到 2030 年，它将成为肝移植和肝细胞癌的主要原因。NAFLD 的传统药物治疗并不完善。在这种情况下，顺势疗法为治疗 NAFLD 提供了一种有前途的选择。

目的

本综述旨在收集用于治疗 NAFLD 的顺势疗法药物的信息，旨在提供其疗效的证据，并深入探讨这些顺势疗法药物在 NAFLD 中发挥治疗作用的机制。

方法

对经典顺势疗法文献进行了全面探讨，参考了可靠的文本，以提取有关 NAFLD 及其在顺势疗法中的治疗的相关信息。系统地搜索了电子数据库，包括 PubMed、Science Direct 和 Google Scholar，以收集有关顺势疗法药物治疗 NAFLD 疗效的信息。

结果

顺势疗法提供了丰富的单草药和复方制剂库。有大约 32 种单草药和 18 种复方制剂用于治疗 NAFLD 的描述。这些药物通过其 Musakhkhin（发热）、Mudirr（利尿剂）、Mufattiḥ（通便剂）、Muqawwῑ-i-Jigar（保肝）和 Muḥallilat（抗炎）作用起作用。这些药物中的生物活性成分具有抗氧化、降血脂、抗炎、降血糖和保肝作用。这些顺势疗法药物的作用与 NAFLD 发病机制的多方面性质密切相关，因此对治疗 NAFLD 有效。